Last update 21 Nov 2024

CD79b-19 CAR T Cells(Massachusetts General Hospital)

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms-
Target
CD19 x CD79B
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators), CD79B modulators(B-cell antigen receptor complex-associated protein beta chain modulators), Immunologic cytotoxicity
+ [1]
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [1]
Active Indication
Follicular LymphomaHigh grade B-cell lymphomaMantle-Cell Lymphoma+ [4]
Inactive Indication-
Originator Organization
The Schwartz Center for Compassionate HealthcareThe Schwartz Center for Compassionate Healthcare
Active Organization
The General Hospital Corp.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with CD79b-19 CAR T Cells(Massachusetts General Hospital)
NCT06026319 / RecruitingPhase 1IIT
A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
100 Clinical Results associated with CD79b-19 CAR T Cells(Massachusetts General Hospital)
Login to view more data
100 Translational Medicine associated with CD79b-19 CAR T Cells(Massachusetts General Hospital)
Login to view more data
100 Patents (Medical) associated with CD79b-19 CAR T Cells(Massachusetts General Hospital)
Login to view more data
100 Deals associated with CD79b-19 CAR T Cells(Massachusetts General Hospital)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Follicular LymphomaPhase 1
US
The General Hospital Corp.
26 Oct 2023
High grade B-cell lymphomaPhase 1
US
The General Hospital Corp.
26 Oct 2023
Mantle-Cell LymphomaPhase 1
US
The General Hospital Corp.
26 Oct 2023
Marginal Zone B-Cell LymphomaPhase 1
US
The General Hospital Corp.
26 Oct 2023
Mediastinal large B-cell lymphomaPhase 1
US
The General Hospital Corp.
26 Oct 2023
Non-Hodgkin's lymphoma refractoryPhase 1
US
The General Hospital Corp.
26 Oct 2023
Recurrent Non-Hodgkin LymphomaPhase 1
US
The General Hospital Corp.
26 Oct 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free